Skip to main navigation
Wave Life Sciences logo
  • Patients & Families
  • Investors
  • Careers
  • Follow Us
    • X X
    • LinkedIn LinkedIn
    • Glassdoor Glassdoor
  • Company
    • Leadership Team
    • DEI
    • Corporate Responsibility
    • Contact Us
  • Science
    • PRISM™ Platform
    • Publications
    • Collaborations
    • Manufacturing
  • Pipeline
    • R&D Pipeline
    • Clinical Programs
  • News
    • Press Releases
  • Home
  • Investors
  • SCHEDULE 13D/A
  • Company
    • Leadership Team
    • DEI
    • Corporate Responsibility
    • Contact Us
  • Science
    • PRISM™ Platform
    • Publications
    • Collaborations
    • Manufacturing
  • Pipeline
    • R&D Pipeline
    • Clinical Programs
  • News
    • Press Releases
line divider for mobile navigation
  • Patients & Families
  • Investors
  • Careers
  • Follow Us
    • X X
    • LinkedIn LinkedIn
    • Glassdoor Glassdoor
Search

Reimagining RNA medicine

  • Menu Icon arrow mobile
  • Overview
  • News
  • Events & Publications
  • SEC Filings
  • Stock Information
  • Analyst Coverage
  • Corporate Governance
  • FAQs

Document Details

Form
SCHEDULE 13D/A
Filing Date
Dec 15, 2025
Document Date
Dec 15, 2025
Form Description
SCHEDULE 13D/A - Description
Filing Group
Other
Company
Wave Life Sciences
Issuer
WAVE LIFE SCIENCES LTD.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Investor Inquiries

Kate Rausch

Investor Relations

617-949-4827

InvestorRelations@wavelifesci.com

Request information

Email Alerts

Sign up here to receive email alerts from Wave Life Sciences.

Sign up
WAVE Life Sciences logo
  • Company
  • Leadership Team
  • DEI
  • Corporate Responsibility
  • Contact Us
  • Science
  • PRISM™ Platform
  • Publications
  • Collaborations
  • Manufacturing
  • Pipeline
  • R&D Pipeline
  • Clinical Programs
  • News
  • Press Releases

© 2026 Wave Life Sciences. All Rights Reserved.

  • Privacy
  • Terms of use
  • Contact